Hong Kong Exchanges and Clearing

Hong Kong Exchanges and Clearing operates as one of the world’s largest exchange groups by market capitalization. It runs equity, commodity, fixed income, and currency markets through subsidiaries including The Stock Exchange of Hong Kong Limited (SEHK), Hong Kong Futures Exchange Limited (HKFE), and London Metal Exchange (LME). It also operates several clearing houses in Hong Kong. While not itself a life sciences or healthcare company, HKEX has become a major listing venue for biotech companies since 2018 due to regulatory changes that allow pre-revenue biotech firms to list on its exchange[1][2][8].

As of December 2024:

• Market capitalization ~US$35 trillion.
• Over 2,600 listed companies.
• World’s leading IPO market; significant focus on attracting innovative/biotech listings[2][8].

The company does not develop drugs or medical products but provides capital markets infrastructure for such companies to raise funds.

Notable acquisition:

• Acquired the London Metal Exchange in December 2012[2][5].

Largest shareholder:

• The Government of the Hong Kong Special Administrative Region[2].

Key role in biotech sector:

• Since April 2018 allows pre-revenue biotech companies to list under Chapter 18A rules; over HK$84 billion raised by such firms between launch and May 2021[6][8].

However, these are listings hosted by HKEX—not products or programs developed by HKEX itself.